Linklaters has advised Theramex (a portfolio company of Carlyle and PAI Partners) on Theramex’s proposed acquisition of certain rights and assets relating to the menopause therapy drugs Femoston and Duphaston from Viatris, Inc., a NASDAQ-listed pharmaceutical company. Theramex is a global speciality pharmaceutical company, solely committed to women’s health, operating in 80+ countries, with 500+ […]
The post Linklaters advises Theramex (a portfolio company of PAI Partners and Carlyle) on Theramex’s proposed acquisition of Duphaston and Femoston oral menopause drugs from Viatris appeared first on Legal Desire Media and Insights.